The FDA’s Center for Devices and Radiological Health (CDRH) has a clear regulatory approach for many types of artificial intelligence (AI)-enabled devices, but new clinical indications or new types of AI require novel assessment paradigms (for both non-clinical and clinical testing) to determine safety and effectiveness.